BPA for imicivree
Active Awarded Last action
- Contract number
- 36E79722A0006
- Awardee
-
Rhythm Pharmaceuticals, Inc. UEI G9KGU2YDQNU4
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 99% complete
- IDV ceiling
- $375,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Rhythm Pharmaceuticals, Inc. was awarded a single award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs (VA) National Acquisition Center to supply Imicivree, a pharmaceutical treatment for obesity and hyperphagia caused by Prader-Willi syndrome. The BPA carries a ceiling value of $375,000 and was established on November 3, 2021, with an ultimate completion date of November 3, 2026. No set-asides were applied to this contract award. The contract falls under the parent GSA Schedule for Pharmaceuticals and Drugs (FSS-61-IB), which facilitates the procurement of pharmaceutical products across federal agencies. This BPA structure enables the VA to place orders for Imicivree against the established ceiling without requiring separate competitive solicitation for each purchase.
The VA's National Acquisition Center utilized this BPA mechanism to streamline procurement of Imicivree while incorporating 2026 Public Law pricing updates, ensuring that medication costs align with current legislative pricing requirements. The five-year performance period demonstrates the VA's commitment to maintaining consistent supply of this specialized pharmaceutical for eligible veteran populations. As a for-profit pharmaceutical company active in the federal marketplace and registered in the System for Award Management (SAM.gov), Rhythm Pharmaceuticals maintains multiple federal contract vehicles focused on pharmaceutical distribution, positioning it as an established provider within the federal health care supply chain. The single award structure reflects the specialized nature of Imicivree procurement, as this medication addresses a specific rare disease indication.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79722A0006?
36E79722A0006 was awarded to Rhythm Pharmaceuticals, Inc. by National Acquisition Center (Headquarters) on November 3, 2021.
How much is contract 36E79722A0006 worth?
36E79722A0006's own ceiling is $375,000.
Who can order from contract 36E79722A0006?
36E79722A0006 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79722A0006 under another contract?
Yes. 36E79722A0006 is a blanket purchase agreement under 36F79722D0014, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79722A0006 competed?
The extent of competition for 36E79722A0006 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV